Literature DB >> 26816081

D-SAL and NAP: Two Peptides Sharing a SIP Domain.

Illana Gozes1, Shlomo Sragovich2, Yulie Schirer2, Anat Idan-Feldman2.   

Abstract

NAPVSIPQ (NAP) and all D-amino acid SALLRSIPA (D-SAL) are neuroprotective peptides derived from activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF), respectively. Both proteins were shown to protect against cognitive impairment, using different animal models and to increase neuronal survival following exposure to neurotoxins. NAP was extensively tested and found to increase microtubule stability, protect axonal transport, and inhibit apoptosis. Here, we aimed to further evaluate and correlate effects at the behavioral level, in a rat model of diabetes. Diabetes is primarily a metabolic disorder which presents secondary neurological manifestations. Diabetes induces peripheral nervous system damage which is translated into impaired sensory perception and is termed diabetic neuropathy. Diabetes-related central nervous system damage causes cognitive decline. The behavioral study aimed to evaluate the effect of NAP and D-SAL on peripheral neuropathy and cognitive decline. Peripheral neuropathy was tested by measuring the response to a thermal stimulus, and cognitive ability was measured by a social memory test and a spatial memory test using long- and short-term dependent tasks and a reference memory task. Results indicated an immediate sensory neuropathy in the diabetic model, which was prevented by both peptides and a later neuropathic phase, prevented only by NAP treatment. Cognitive tests revealed impaired performance in both social and spatial memory tests in the diabetes model. Each of the peptides improved different aspects of cognitive behavior, with NAP being more potent than D-SAL. Mechanistically, both NAP and SAL contain a SIP (SxIP) domain that has been shown to interact with microtubule end-binding proteins (EBs). Specifically, we have previously shown a direct interaction of NAP with EB1 and EB3; we have further shown an interaction of the NAP-derived 4 amino acid SKIP peptide with EB3, stimulating axonal transport. Interestingly, the all D-amino acid peptide, D-SKIP, only partially mimicked SKIP activity. Our current results implicate D-SAL activity with potentially reduced potency compared to NAP, partially mimicking the SKIP/D-SKIP results and placing the SIP (SxIP) motif as a central focus for microtubule-based neuroprotection.

Entities:  

Keywords:  ADNF (activity-dependent neurotrophic factor); ADNP (activity-dependent neuroprotective protein); D-SAL (all D-amino acid SALLRSIPA); NAP (NAPVISPQ); SIP (SxIP) the peptide motif interacting with microtubule end binding proteins

Mesh:

Substances:

Year:  2016        PMID: 26816081     DOI: 10.1007/s12031-015-0701-8

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  64 in total

1.  Dinuclear Zn(2+) complexes of synthetic heptapeptides as artificial nucleases.

Authors:  C Sissi; P Rossi; F Felluga; F Formaggio; M Palumbo; P Tecilla; C Toniolo; P Scrimin
Journal:  J Am Chem Soc       Date:  2001-04-04       Impact factor: 15.419

2.  Learning enhancement with neuropeptides.

Authors:  Laura Toso; Melanie Endres; Joy Vink; Daniel T Abebe; Douglas E Brenneman; Catherine Y Spong
Journal:  Am J Obstet Gynecol       Date:  2006-04       Impact factor: 8.661

Review 3.  Thermoreceptors and thermosensitive afferents.

Authors:  Raf J Schepers; Matthias Ringkamp
Journal:  Neurosci Biobehav Rev       Date:  2008-08-07       Impact factor: 8.989

Review 4.  Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.

Authors:  Natalia Shiryaev; Regina Pikman; Eliezer Giladi; Illana Gozes
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

5.  Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia.

Authors:  Efrat Dresner; Galila Agam; Illana Gozes
Journal:  Eur Neuropsychopharmacol       Date:  2010-07-03       Impact factor: 4.600

6.  Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory.

Authors:  N Amram; G Hacohen-Kleiman; S Sragovich; A Malishkevich; J Katz; O Touloumi; R Lagoudaki; N C Grigoriadis; E Giladi; A Yeheskel; M Pasmanik-Chor; Y Jouroukhin; I Gozes
Journal:  Mol Psychiatry       Date:  2016-01-19       Impact factor: 15.992

7.  Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model.

Authors:  Anat Idan-Feldman; Yulie Schirer; Eleni Polyzoidou; Olga Touloumi; Roza Lagoudaki; Nikolaos C Grigoriadis; Illana Gozes
Journal:  Neurobiol Dis       Date:  2011-07-27       Impact factor: 5.996

8.  Activity-dependent neuroprotector homeobox protein: A candidate protein identified in serum as diagnostic biomarker for Alzheimer's disease.

Authors:  Ming-Hui Yang; Yuan-Han Yang; Chi-Yu Lu; Shiang-Bin Jong; Li-Jhen Chen; Yu-Fen Lin; Shyh-Jong Wu; Pei-Yu Chu; Tze-Wen Chung; Yu-Chang Tyan
Journal:  J Proteomics       Date:  2012-04-21       Impact factor: 4.044

9.  Reduced growth and skeletal changes in zinc-deficient growing rats are due to impaired growth plate activity and inanition.

Authors:  L Rossi; S Migliaccio; A Corsi; M Marzia; P Bianco; A Teti; L Gambelli; S Cianfarani; F Paoletti; F Branca
Journal:  J Nutr       Date:  2001-04       Impact factor: 4.798

10.  Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment.

Authors:  G J Biessels; A Kamal; I J Urban; B M Spruijt; D W Erkelens; W H Gispen
Journal:  Brain Res       Date:  1998-07-27       Impact factor: 3.252

View more
  5 in total

1.  Microtubule stabilising peptides rescue tau phenotypes in-vivo.

Authors:  Shmma Quraishe; Megan Sealey; Louise Cranfield; Amritpal Mudher
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

2.  The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings.

Authors:  Illana Gozes; Marc C Patterson; Anke Van Dijck; R Frank Kooy; Joseph N Peeden; Jacob A Eichenberger; Angela Zawacki-Downing; Sandra Bedrosian-Sermone
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-19       Impact factor: 5.555

3.  A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP.

Authors:  Yanina Ivashko-Pachima; Illana Gozes
Journal:  Front Cell Neurosci       Date:  2019-10-01       Impact factor: 5.505

4.  An evolutionary roadmap to the microtubule-associated protein MAP Tau.

Authors:  Frederik Sündermann; Maria-Pilar Fernandez; Reginald O Morgan
Journal:  BMC Genomics       Date:  2016-03-31       Impact factor: 3.969

5.  ADNP, a Microtubule Interacting Protein, Provides Neuroprotection Through End Binding Proteins and Tau: An Amplifier Effect.

Authors:  Illana Gozes; Yanina Ivashko-Pachima; Carmen L Sayas
Journal:  Front Mol Neurosci       Date:  2018-05-01       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.